Dr Camille Carroll
Profiles

Dr Camille Carroll

Post Doctoral Research Fellow in Clinical Neuroscience

Clinical Trials & Health Research - Institute of Translational & Stratified Medicine (Faculty of Medicine and Dentistry)

Role

Honorary Consultant Neurologist, Plymouth Hospitals NHS Trust

National Specialty Lead for Neurodegenerative Diseases NIHR CRN

Parkinson’s Specialty Lead and Cluster 4 Clinical Research Lead South West Peninsula CRN


Integrated Clinical Academic Training Lead


Qualifications

Dr Carroll is an academic consultant neurologist. She undertook her preclinical medical training at the University of Manchester,where she also completed an intercalated PhD (1994) investigating NMDA receptor antagonists in models of Parkinson's disease (PD). She completed her clinical training at the University of Oxford in 1997 and undertook specialist neurology training in the South West and West Midlands. In 2007 Dr Carroll was awarded a Medical Research Council fellowship which allowed her to develop research interests investigating neuroprotective mechanisms in cell culture models of Parkinson's disease. 



Roles on external bodies

Dr Carroll sits on the Grant Assessment Panel 1 for Parkinson's UK, the Research Committee for the Cure Parkinson's Trust and the Linked Clinical Trials Committee. She has previously chaired the Data Monitoring Committee for the GDNF trial in Parkinson's disease. She is regional representative on the Association of British Neurologists Research Committee. She is a member of the  Examination Board  and  Question Writing Group  for the Neurology SCE.

Research interests

Dr Carroll's current research focus is on clinical trials of neuroprotective interventions in Parkinson's disease, currently being the chief investigator of a multi-centre clinical trial of simvastatin as a potential neuroprotective therapy in PD (PD-STAT). She also has an interest in the use of technology (wearable sensors and apps) for early disease detection, personalising therapy and monitoring disease progression. She has overseen the development of a PD DNA bank (2700 samples) and a regional PD clinical research register. She was appointed National Specialty Lead for Neurodegenerative Disease in 2017. She has been PD Speciality Lead, South West Peninsula CRN since April 2014, previously being joint PD Research Director for SW DeNDRoN (2010-2014). She was Chair of the Peninsula Parkinson’s Excellence Network (PenPEN) (2015-2017).

Within University Hospitals Plymouth NHS Trust, Dr Carroll leads development of the Parkinson’s disease service, which won a Parkinson's Excellence Network Award in 2017. She also leads a successful trial delivery team, overseeing a mixed portfolio of Parkinson's clinical studies - commercial and non-commercial, interventional and observational. 

Research groups

Key publications are highlighted

Journals
Articles
Carroll CB & Wyse RKH 2017 'Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress' Journal of Parkinson's Disease , DOI PEARL
Lubbe SJ, Escott-Price V, Brice A, Gasser T, Pittman AM, Bras J, Hardy J, Heutink P, Wood NM & Singleton AB 2016 'Rare variants analysis of cutaneous malignant melanoma genes in Parkinson's disease' Neurobiology of Aging 48, 222.e1-222.e7 , DOI PEARL
Zeissler M-L, Eastwood J, McCorry K, Hanemann OC, Zajicek JP & Carroll CB 2016 'Delta-9-tetrahydrocannabinol protects against MPP<sup>+</sup> toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis' Oncotarget , DOI PEARL
Jammeh E, Zhao P, Carroll C, Pearson S & Ifeachor E 2016 'Identification of blood biomarkers for use in point of care diagnosis tool for Alzheimer's disease' 2016 38TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC) 2415-2418 Author Site PEARL
Chaudhuri KR, Rizos A, Trenkwalder C, Rascol O, Pal S, Martino D, Carroll C, Paviour D, Falup-Pecurariu C & Kessel B 2015 'King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation' Movement Disorders 30, (12) 1623-1631 , DOI PEARL
Kamel Boulos MN, Ifeachor E, Escudero Rodriguez J, Zhao P, Carroll CB, Costa P, Doppler G, Carrasco L, Spiru L & Helga K 2015 'LiveWell - Promoting Healthy Living and Wellbeing for Parkinson Patients Through Social Network and ICT Training: Lessons Learnt and Best Practices' International Journal of Healthcare Information Systems and Informatics
Cooke T, Carroll C, Zajicek J, Ellard S & Morrison K 2013 'Molecular genetic studies of neurodegenerative disease' J Neurol Neurosurg Psychiatry 84, (11) Author Site , DOI PEARL
Zeissler M, Eastwood J, Oliver Hanemann C, Zajicek J & Carroll C 2013 'Δ9–TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPARγ DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE' Journal of Neurology, Neurosurgery & Psychiatry 84, (11) e2.58-e2 , DOI PEARL
Hilton D, Stephens M, Kirk L, Edwards P, Potter R, Zajicek J, Broughton E, Hagan H & Carroll C 2013 'Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease' Acta Neuropathologica 1-7 Author Site , DOI
Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, Carroll C & Hanemann CO 2012 'The role of insulin-like growth factors signaling in merlin-deficient human schwannomas' Glia 60, (11) 1721-1733 Author Site , DOI PEARL
Carroll CB, Zeissler M-L, Hanemann CO & Zajicek JP 2012 'Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease' Neuropathol Appl Neurobiol 38, (6) 535-547 Author Site , DOI
Carroll C, Palmer A, Cosby C & Zajicek J 2012 'Analysis and validation of a Parkinson's disease register as a recruitment tool for clinical studies' Clin Med (Lond) 12, (3) 210-215 Author Site PEARL
Carroll C, Palmer A, Cosby C & Zajicek J 2011 'Analysis and validation of a Parkinson's disease register as a recruitment tool for clinical studies' CLINICAL MEDICINE 12, (3) 210-215 Author Site , DOI
Carroll CB, Zeissler M-L, Chadborn N, Gibson K, Williams G, Zajicek JP, Morrison KE & Hanemann CO 2011 'Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease' Neurochem Int 59, (1) 73-80 Author Site , DOI PEARL
Carroll CB & Zajicek JP 2011 'Designing clinical trials in older people' Maturitas 68, (4) 337-341 Author Site , DOI PEARL
Carroll C, Krolikowski K, Mukonoweshuro W, Jones J & Hanemann CO 2010 'Unilateral cerebral hemisphere oedema as a peri-ictal phenomenon' J Neurol 257, (12) 2094-2096 Author Site , DOI
Carroll CB, Zeissler ML, Stone V, Hanemann CO & Zajicek JP 2010 'Cannabinoids Are Neuroprotective in a Human Cell Culture Model of Parkinson's Disease' MOVEMENT DISORDERS 25, S621-S621 Author Site PEARL
Carroll CB, Zeissler ML, Chadborn N, Gibson K, Williams GJ, Morrison KE, Zajicek JP & Hanemann CO 2010 'Changes in Iron-Regulatory Gene Expression Occur in Human Cell Culture Models of PD' MOVEMENT DISORDERS 25, S628-S628 Author Site PEARL
Zeissler, Carroll CB & Zajicek J 2010 'CBD & D9-THC - the two faces of cannabis' Cell Science 7, (1)
Sinclair AJ, Carroll C & Davies B 2009 'Cauda equina syndrome following a lumbar puncture' J Clin Neurosci 16, (5) 714-716 Author Site , DOI PEARL
Katzenschlager R, Schrag A, Evans A, Manson A, Carroll CB, Ottaviani D, Lees AJ & Hobart J 2007 'Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure' Neurology 69, (6) 555-563 Author Site , DOI
Carroll CB, Tengah DSNAP, Lawthom C & Venables G 2007 'The feminisation of British neurology: implications for workforce planning' Clin Med (Lond) 7, (4) 339-342 Author Site PEARL
Goodall EF, Greenway MJ, van Marion I, Carroll CB, Hardiman O & Morrison KE 2005 'Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS' Neurology 65, (6) 934-937 Author Site , DOI
Liu XG, Carroll CB, Wang SY, Zajicek J & Bain PG 2005 'Quantifying drug-induced dyskinesias in the arms using digitised spiral-drawing tasks' JOURNAL OF NEUROSCIENCE METHODS 144, (1) 47-52 Author Site , DOI PEARL
Carroll CB, Hilton DA, Hamon M & Zajicek JP 2005 'Muscle cramps and weakness secondary to graft versus host disease fasciitis' Eur J Neurol 12, (4) 320-322 Author Site , DOI PEARL
McSherry JW, Carroll CB, Zajicek J, Teare L & Bain P 2005 'Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study' Neurology 64, (6) 1100-1100 , DOI
Carroll CB & Zajicek JP 2004 'The 'harlequin' sign in association with multiple sclerosis' JOURNAL OF NEUROLOGY 251, (9) 1145-1146 Author Site , DOI
Carroll CB & Bain PG 2004 'Doon-off variations cause discrepancies in the historical items of the UPDRS?' Movement Disorders 19, (5) 605-605 , DOI PEARL
Fox P, Bain PG, Glickman S, Carroll C & Zajicek J 2004 'The effect of cannabis on tremor in patients with multiple sclerosis' Neurology 62, (7) 1105-1109 Author Site
Carroll C, Hobart J, Fox C, Teare L & Gibson J 2004 'Stroke in Devon: knowledge was good, but action was poor' J Neurol Neurosurg Psychiatry 75, (4) 567-571 Author Site PEARL
Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D & Hobart J 2004 'Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study' Neurology 63, (7) 1245-1250 Author Site
Carroll C & Zajicek J 2004 'Provision of 24 hour acute neurology care by neurologists: manpower requirements in the UK' J Neurol Neurosurg Psychiatry 75, (3) 406-409 Author Site PEARL
Carroll CB & Gardner-Thorpe C 2004 'Charles Karsner Mills (1845-1931) and his syndrome' Some Aspects of History of Neuroscience 35-36
Hadjikoutis S, Carroll CB & Plant GTP 2004 'Raised intracranial pressure presenting with spontaneous periorbital bruising: two case reports' Journal of Neurology, Neurosurgery and Psychiatry 75, (8) PEARL
Weeks RA, Scaravilli F, Lees AJ, Carroll CB, Husain M & Rudge P 2003 'Cerebral amyloid angiopathy and motor neurone disease presenting with a progressive supranuclear palsy-like syndrome' Movement Disorders 18, (3)
Cooper AJ, Carroll CB & Mitchell IJ 1998 'Glutamate antagonists for Parkinson's disease - Rationale for use and therapeutic implications' CNS DRUGS 9, (6) 421-429 Author Site , DOI
Scott R 1998 'Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson's disease. A consecutive series of eight simultaneous bilateral and twelve unilateral procedures' Brain 121, (4) 659-675 , DOI
Carroll CB, Scott R, Davies LE & Aziz T 1998 'The pallidotomy debate' British Journal of Neurosurgery 2, (12)
B. CARROLL C, SCOTT R, DAVIES LE & AZIZ T 1998 'The pallidotomy debate' British Journal of Neurosurgery 12, (2) 146-150 , DOI
Biousse V, Newman NJ, Carroll CB, Mewes K, Vitek JL, Bakay RAE, Baron MS & DeLong MR 1998 'Visual fields in patients with posterior GPi pallidotomy'
Mitchell IJ & Carroll CB 1997 'Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action' Neurosci Biobehav Rev 21, (4) 469-475 Author Site PEARL
MITCHELL IJ, HUGHES N, CARROLL CB & BROTCHIE JM 1995 'REVERSAL OF PARKINSONIAN SYMPTOMS BY INTRASTRIATAL AND SYSTEMIC MANIPULATIONS OF EXCITATORY AMINO-ACID AND DOPAMINE TRANSMISSION IN THE BILATERAL 6-OHDA LESIONED MARMOSET' BEHAVIOURAL PHARMACOLOGY 6, (5-6) 492-507 Author Site
Carroll CB, Holloway V, Brotchie JM & Mitchell IJ 1995 'Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: Functional implications for treatment of parkinsonian symptoms' Psychopharmacology 119, (1) 55-65 , DOI
Brotchie JM, Crossman ARC, Mitchell IJ, Duty S, Carroll CB, Cooper AJC, Henry B, Hughes N & Maneuf Y 1993 'Chemical signalling in the globus pallidus in parkinsonism' Progress in Brain Research (99) 125-139